Research Article

Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Hao Liao,1 Le Li,2 Wei V. Zheng,1 Jun Zou,3 Guangxin Yu,3 Lanlan Si,2 Feilin Ge,2 Tao Zhou,1 Dong Ji,2 Xiangmei Chen,3 Dongping Xu,2 Guanxun Cheng,1 Yan Liu,2 and Junhui Chen1

1Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518035 Guangdong Province, China
2Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
3Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

Correspondence should be addressed to Guanxun Cheng; chengguanxun@outlook.com, Yan Liu; liuyan5360@163.com, and Junhui Chen; chenjhpush@outlook.com

Received 4 April 2022; Accepted 16 June 2022; Published 14 July 2022

Academic Editor: Luciano Colangelo

Copyright © 2022 Hao Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and aims. To investigate the clinical implications of serum HBV RNA, serum hepatitis B core-related antigen (HBcrAg), and quantitative anti-HBc in treatment-naïve patients with chronic HBV infection. Methods. A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic covalently closed circular DNA (cccDNA) were quantified and each of these indicator’s correlation with liver inflammation was analyzed. Results. HBeAg-positive individuals had significant higher serum levels of HBV RNA and HBcrAg than those who were HBeAg negative, similar to that of serum HBV DNA. Comparatively, HBV RNA (r = 0.79, P < 0.01) and HBcrAg (r = 0.78, P < 0.01) had almost same higher overall correlation with the cccDNA, as that of HBV DNA (r = 0.81, P < 0.01). Serum anti-HBc level (r = -0.52, P < 0.05) is negatively correlated with cccDNA level at IT phase rather than the other three phases. When set the cutoff value at 4.00 log10 IU/mL, serum anti-HBc showed potential to indicate liver inflammation, with AUC as 0.79 and the specificities as 78.85% for HBeAg positive, and with AUC as 0.72 and the specificities as 62.16% for HBeAg-negative patients, respectively. Conclusions. In treatment-naïve patients, levels of serological markers HBV RNA and HBcrAg could mirror intrahepatic cccDNA level, but were not superior to HBV DNA level. Serum anti-HBc level had certain potential to be used as a predicting marker for liver inflammation.

1. Introduction

An estimated 257–291 million people worldwide are chronically infected with hepatitis B virus (HBV), and the interaction between HBV replication and the host immune response may lead to a variety of clinical complications from inflammation to liver cirrhosis and hepatocellular carcinoma [1]. The natural history of chronic HBV infection has been divided into four or five phases, according to the American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) [2, 3]. AASLD suggested the four phases of natural history (immune-tolerant phase, HBeAg-positive immune-active phase, inactive CHB phase, and HBeAg-negative immune reactivation phase); each phase has distinct characteristics on the HBeAg, HBV DNA levels, alanine aminotransferase (ALT) values, and grades of liver inflammation.

Not all patients with chronic HBV infection have chronic hepatitis (CHB), and monitoring viral replication is important for the management of HBV. At the same time,
high levels of replication do not necessarily predict high levels of inflammation, so indicators of viral replication (HBV DNA or covalently closed circular DNA (cccDNA)), serological markers, and liver inflammation should all be considered in determining whether and when to initiate treatment. The cccDNA, as the template of HBV transcription, contributes to infection persistence [4, 5]. Recently, novel surrogate makers of cccDNA including serum hepatitis B core-related antigen (HBcrAg) and HBV RNA have attracted research interest [6]. Our previous study, as well as work by others, have demonstrated that serum HBV RNA from the pgRNA are not or partially reverse transcribed in encapsidated particles [7], which may reflect cccDNA transcriptional activity [8, 9]. Serum HBV RNA may be an early clinical indicator of HBeAg seroconversion, virological response, and HBsAg reversion during pegylated interferon-α or nucleoside/nucleotide analogues (NAs) antiviral therapy [10–12]. Serum HBcrAg has an excellent correlation with cccDNA transcription in CHB patients and is also suggested as a serum marker for cccDNA [13]. In addition, HBcrAg shows high diagnostic performance in the accurate identification of patients with HBeAg-negative CHB [14]. When serum HBV DNA level is too low to be detected, monitoring HBV RNA and HBcrAg can be used to reflect viral replication in NAs-treated patients [15]. In addition, it has been reported that serum hepatitis B core antibody (anti-HBc) levels in CHB patients are useful markers of NAs and pegylated interferon therapy efficacy [16, 17]. More importantly, serum anti-HBc is part of the host HBV-specific adaptive immune component, and elevated anti-HBc levels in CHB patients with normal alanine aminotransferase indicate liver inflammation [18, 19].

Although the clinical characteristics of HBcrAg, HBV RNA, and anti-HBc have been studied before, they had not been studied in one cohort of patients. In this study, we provided a comprehensive picture of all these serological markers and indicators of viral replication in relation to liver inflammation in untreated patients across the distinct phases of HBV chronic infection, with an emphasis on the serum anti-HBc.

2. Methods

2.1. Patients and Study Design. The study included a cross-sectional set of 111 treatment-naïve CHB patients, of whom 21 (18.92%) were in the immune-tolerant (IT) phase, 49 (44.14%) in the immune-clearance (IC) phase, 29 (26.13%) in the low replicative (LR) phase, and 12 (10.81%) in the reactivation phase. Disease phases were categorized referring to the Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update [20]. All patients were recruited from the Fifth Medical Center of PLA General Hospital from January 2017 to December 2019. Only patients with liver biopsy were included. There was no evidence for concomitant HCV, HDV, or HIV infection or alcoholic liver disease, autoimmune liver disease. Patients with cirrhosis and hepatocellular carcinoma were excluded. Fibrosis and necro-inflammatory activity were quantified by experienced histopathologists using the METAVIR criteria [21]. At the time of liver biopsy, serum samples were collected and stored at -80°C until use. The Ethics Committee of the Fifth Medical Center of PLA General Hospital approved the study protocol. The enrolled patients met the requirement for inclusion in the database of the Fifth Medical Center of PLA General Hospital. Written informed consent was obtained from all patients.

2.2. Determination of HBV DNA and Serological HBV Markers. HBeAg and HBsAg levels were determined using a Roche Cobas e601 analyzer (Roche Diagnostics Ltd., Burgess Hill, UK) and expressed according to a cutoff index. HBsAg quantification was performed using Roche Cobas e601 (Roche Diagnostics) with a 0.05–250 IU/mL linear detection range for HBsAg. Real-time fluorescent quantitative PCR was used to quantify serum HBV DNA, and the method has a lower limit of quantitation (LLOQ) of 20 IU/mL.

2.3. Quantitation of Serum Anti-HBc, HBV RNA, and HBcrAg. Serum anti-HBc was quantified on the Caris 200 Platform following the kit manufacturer’s instructions (Wantai, Beijing, China) using a recently developed double-sandwich immunoassay method. Calibration standards of the assay used standards provided by the World Health Organization. The assay has a LLOQ of 0.25 IU/mL and a linear detection range of 2.5–250 IU/mL.

After serum HBV RNA was extracted, one-step real-time RT-PCR amplification was performed according to the kit manufacturer’s instructions (Beijing Hotgen Biotech Co., Ltd., Beijing, China). The assay has a LLOQ of 100 copies/mL and a linear detection range of 3–8 log10 copies/mL. Values below the LLOQ were defined as half of constant LLOQ, i.e., 50 copies/mL in statistical analysis.

Serum HBcrAg levels were determined using a chemiluminescent enzyme immunoassay according to the kit manufacturer’s instructions (Lumipulse System, Fujirebio Inc., Tokyo, Japan). The assay has a LLOQ of 1,000 U/mL and a linear detection range of 3–7 log10 U/mL. Samples with a value beyond detection limit were retested at a 1:100 dilution. Values below the LLOQ (not quantifiable but detectable) were still recorded and analyzed.

2.4. Quantitation of Intrahepatic HBV Total DNA and cccDNA. Quantitation and quantification of intrahepatic HBV cccDNA were performed as we previously described [22]. First, the intracellular free-microchromosomal DNA and genomic DNA were extracted by the QIAamp DNA Mini Kit according to the manufacturer’s instructions (QIAGEN, GmbH, Hilden, Germany). PSAD was applied to digest HBV dsDNA, rcDNA, and ssDNA (Epicentre, Madison, WI, USA). Then, cccDNA-selective amplification was performed using Rolling Circle Amplification (RCA) method with Phi29 DNA polymerase (New England Biolabs, Worcester, MA). The RCA products were subjected to further amplification and quantification using TaqMan real-time PCR mediated by probes targeting gap regions of the viral genome and a cccDNA-selective primer pair. PSAD and phi29 DNA polymerase treatment was not required for detection of HBV total DNA. Number of cells was calculated.
The area under the receiver-operating characteristic (AUC) graphical analyses and data presentation. A two-tailed GraphPad Prism (version 8.0) was the software used for IBM SPSS (version 21) was used for all statistical analyses. The diagnostic validity of variables was determined using Spearman’s method. The diagnostic validity of variables was defined as the area under the receiver-operating characteristic (AUC) curve, and the difference was tested by McNeil and Hanley. IBM SPSS (version 21) was used for all statistical analyses. GraphPad Prism (version 8.0) was the software used for graphical analyses and data presentation. A two-tailed P value < 0.05 was considered statistically significant.

### 3. Results

#### 3.1. Clinical Characteristics of Patients

This study recruited a total of 111 antiviral treatment naïve individuals with chronic HBV infection at distinct disease progression phases, with a median age of 35 (29, 42) yrs, and 61.26% (68/111) were male (Table 1). Among whom, 70 (63.06%) were HBeAg positive and 41 (36.94%) were HBeAg negative. Significantly elevated ALT (35 U/L is upper limit of ALT normal) and aspartate aminotransferase (AST, 40 U/L is upper limit of AST normal) were observed in the IC- or reactivation-phase patients, concordant to the new EASL guideline for the management of CHB [2], in which patients in the IC or reactivation phase were identified as HBeAg-positive or HBeAg-negative CHB patients. As expected, the overall HBV DNA level in HBeAg-negative patients 2.93 (2.24, 3.34) log10 IU/mL was significantly lower than that of HBeAg-positive patients 8.55 (7.85, 9.00) log10 IU/mL (P < 0.001). Noticeably, the serum HBV DNA level in the reactivation phase 4.27 (3.44, 5.08) log10 IU/mL was significantly increased as compared to that of patients in LR phase 2.37 (1.94, 3.04) log10 IU/mL (P < 0.001). Meanwhile, the HBsAg level in HBeAg-positive patients decreased significantly, forming a median of 52010 (36221, 77630) IU/mL in the IT phase to 27173 (5731, 49565) IU/mL in the IC phase (P = 0.009), which were significantly higher than that of HBeAg-negative patients; the medians of HBsAg were 1516 (231, 4814) IU/mL in the LR phase and 1176 (608, 7741) IU/mL in the reactivation phase.

#### 3.2. Serum HBV RNA, HBcAg, Anti-HBc, and Intrahepatic cccDNA Levels across Distinct Disease Phases.

As shown in Figure 1, similar to serum HBV DNA levels, serum HBV RNA levels in the IT-phase and IC-phase patients [6.87 (6.42, 7.00) log10 copies/mL, 6.40 (5.83, 6.83) log10 copies/mL] were significantly higher than those in the LR-phase and reactivation-phase patients [below the LLOQ, 2.39 (1.00, 2.80) log10 copies/mL]. The changes in intrahepatic HBV tDNA and cccDNA levels shared same trend across four disease phases. The cccDNA levels were 6.48 (6.20, 6.79), 6.16 (5.49, 6.74), 3.48 (3.30, 4.32), and 4.36 (3.72, 4.85) log10 copies/10^5 cells for the IT-, IC-, LR-, and reactivation-phased patients, respectively. In HBeAg-positive patients, IT-phase patients had higher serum HBcAg levels than IC-phase patients, and the difference was marginally significant [8.91 (8.42, 9.07)] vs. 8.66 (8.21, 8.96) log10 copies/10^5 cells (P = 0.027).

### Table 1: Clinical and virological details of the treatment-naïve HBV-infected patients.

| Characteristic | HBeAg-positive patients (n=70) | P-value | HBeAg-negative patients (n=41) | P-value |
|---------------|-------------------------------|---------|-------------------------------|---------|
|               | Immune-tolerant phase (n=21) | Immune-clearance phase (n=49) |                   | Low replicative phase (n=29) | Reactivation phase (n=12) |
| Gender, male, n (%) | 7 (33.33) | 32 (65.31) | 0.027 | 18 (62.07) | 11 (91.67) | 0.073 |
| Age, years | 38 (33, 45) | 32 (27, 38) | 0.007 | 38 (31, 42) | 38 (30, 44) | 0.682 |
| HBV DNA, log10 IU/mL | 8.57 (8.12, 9.00) | 8.52 (7.59, 9.00) | 0.636 | 2.37 (1.94, 3.04) | 4.27 (3.44, 5.08) | < 0.001 |
| HBsAg, IU/mL | 52010 (36221, 77630) | 27173 (5731, 49565) | 0.009 | 1516 (231, 4814) | 1176 (608, 7741) | 0.921 |
| HBeAg, COI | 1710 (1447, 1964) | 1674 (853, 1842) | 0.231 | / | / | / |
| ALT, U/L | 25 (19, 33) | 76 (49, 243) | < 0.001 | 19 (17, 28) | 54 (39, 79) | < 0.001 |
| AST, U/L | 25 (19, 30) | 42 (31, 100) | < 0.001 | 21 (18, 25) | 33 (25, 51) | < 0.001 |
| ALB, g/L | 39 (38, 43) | 41 (37, 44) | 0.714 | 43 (40, 45) | 44 (40, 45) | 0.854 |
| TBIL, μmol/L | 12.60 (9.50, 14.90) | 14.70 (11.50, 19.20) | 0.040 | 11.20 (8.70, 16.70) | 16.60 (10.50, 25.00) | 0.088 |
| γ-GT | 19.50 (13.50, 23.00) | 30.00 (18.00, 55.50) | 0.010 | 20.00 (16.00, 29.00) | 25.50 (21.50, 47.30) | 0.015 |

Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALB: albumin; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; n: number of cases; TBIL: total bilirubin; γ-GT: γ-glutamyltransferase. All the results of continuous variable are described as median (interquartile range).
Figure 1: Continued.
Intrahepatic HBV cccDNA levels across the distinct phases of chronic HBV infection. Abbreviations: IT: immune-tolerant phase; IC: immune-clearance phases; LR: low-replicated phase; HBV: hepatitis B virus; HBeAg: hepatitis B surface antigen; HBcrAg: hepatitis B core-related antigen; anti-HBc: hepatitis B core antibody; tDNA: total DNA; cccDNA: covalently closed circular DNA; n: number of cases; ***P < 0.0001; ** 0.0001 < P < 0.001; * 0.001 < P < 0.01; 0.01 < P < 0.05; ns, P > 0.05.

Serum anti-HBc level in the IT phase was the lowest compared with the other three phases, [i.e., 2.93 (1.93, 3.85) vs. 3.97 (3.50, 4.34), 3.63 (3.22, 4.21), and 4.12 (3.90, 4.38) log10 IU/mL]. Notably, the pattern of changes in anti-HBc levels across the four disease phases was different from those of HBV RNA, HBV DNA, and HBcAg levels, with significant increases from IT to IC, and LR to reactivation phase.

3.3. The Correlation between Intrahepatic cccDNA and Serum HBV Markers. Next, Spearman’s correlation coefficients (r) analysis was conducted to assay the correlation of viral marker with cccDNA. As expected, intrahepatic HBV tDNA and cccDNA showed a synchronous correlation trend. Except for anti-HBc, strong correlations were observed between intrahepatic HBV cccDNA level and the HBV serological markers in all patients, in an order from strong to weak as HBV DNA (r = 0.81, P < 0.01) > HBV RNA (r = 0.79, P < 0.01) > HBcAg (r = 0.78, P < 0.01) > HBeAg (r = 0.78, P < 0.01) > HBsAg (r = 0.60, P < 0.01) (Figure 2(a)). Stratified analysis revealed that in HBeAg-positive patients, the correlation between intrahepatic cccDNA and serum HBV DNA (r = 0.30, P < 0.05), HBeAg (r = 0.30, P < 0.05), HBcAg (r = 0.38, P < 0.01), HBeAg (r = 0.41, P < 0.01), and HBsAg (r = 0.34, P < 0.01) was similar (Figure 2(b)), while in HBeAg-negative patients, serum HBV DNA showed a strongly correlation with intrahepatic cccDNA (r = 0.71, P < 0.01), followed by serum HBcAg (r = 0.39, P < 0.05), HBV RNA (r = 0.35, P < 0.05), and no correlation for HBsAg (r = 0.18, P > 0.05) (Figure 2(c)). As a consequence, the correlations between HBsAg and the other HBV markers were poor. However, a much stronger correlation between serum HBV DNA with intrahepatic cccDNA was noticed in those HBeAg-negative patients (r = 0.71, P > 0.01), though in general the other serum HBV markers had weak correlations with the intrahepatic cccDNA in such patients. Interestingly, stratification analysis showed that anti-HBc was negatively correlated with intrahepatic cccDNA in HBeAg-positive patients (r = -0.387, P < 0.05), while in HBeAg-negative patients, the correlation was positive (r = 0.419, P < 0.05).

In HBeAg-positive patients, the correlation of serum HBcAg with serum HBV DNA and RNA was 0.48 (P < 0.01) and 0.46 (P < 0.01) in IT phase, and 0.62 (P < 0.01) and 0.68 (P < 0.01) in IC phase (HBeAg-positive hepatitis), respectively (Figures 2(d) and 2(e)). However, such correlations were only seen in HBeAg-negative patients in general (r = 0.51, P < 0.01 for DNA; r = 0.40, P < 0.05 for RNA, respectively), but neither in low replicative nor in reactivation phases, even though without the interfering of HBeAg on HBcAg measurement, perhaps due to the too small number of patients (Figures 2(f) and 2(g)). On the other hand, the correlation between serum HBV RNA and serum HBV DNA was only seen in patients of IC (HBeAg-positive hepatitis) (r = 0.68, P < 0.01) and reactivation (HBeAg-negative hepatitis) (r = 0.66, P < 0.01) phases, but neither in the HBeAg-positive IT nor in the HBeAg-negative lower replication phases. These result to some extent, different from previous reports.

3.4. The cccDNA Transcription and pgRNA Reverse Transcription Efficiencies across Distinct Disease Phases. The cccDNA transcription efficiency, represented by the ratio of serum HBV RNA to intrahepatic cccDNA (serum HBV RNA/cccDNA), was higher in HBeAg-positive patients (IT and IC) than in HBeAg-negative patients (LR and Reactivation) (1.02 vs. 0.30, P < 0.001, Figure 3). The same was true if the numerator of this ratio is not serum HBV RNA but serum HBV DNA and HBcAg (P < 0.001). Unexpectedly, HBeAg-positive patients had lower ratio of serum HBsAg to intrahepatic cccDNA than HBeAg-negative patients (0.73 vs. 0.83, P < 0.001, Figure 3). The reverse
transcription efficiency of HBV pgRNA was defined as the ratio of serum HBV DNA to the sum of HBV DNA and HBV RNA as we previously suggested [23]. HBeAg-positive patients had lower HBV pgRNA reverse transcription efficiency, compared with HBeAg-negative patients. The pgRNA reverse transcription efficiency median in this study was 0.56, 0.56, 0.70, and 0.67, for IT, IC, LR, and reactivation patients, respectively.
3.5. The Intrahepatic and Serological HBV Markers with Liver Inflammation.

Serum HBsAg, HBeAg, HBV RNA, HBV DNA, HBcrAg, and liver HBV tDNA and HBV cccDNA levels, as well as anti-HBc, were analyzed for their association with liver histological inflammation (Metavir score grades). Univariate and multivariate analyses showed that in addition to biochemical indicators such as ALT and AST, serum anti-HBc level was the only marker showed a correlation with liver inflammation (Table 2). This result was expected as anti-HBc levels were reported to partly indicate host immune response to HBV infection. Further subgroup analysis in the HBeAg-positive patients revealed that patients with moderate to severe liver histological inflammation had higher anti-HBc level than patients with mild or

---

Figure 3: The transcriptional efficiency of cccDNA and the reverse transcription efficiency of pgRNA across distinct disease phases. The transcriptional efficiency of cccDNA was determined by the ratio of serum HBV RNA (a), HBV DNA (b), HBcrAg (c), and HBsAg (d) to intrahepatic cccDNA. The reverse transcription efficiency of HBV pgRNA represented as a ratio of serum HBV RNA to HBV DNA was inversely related (e). The ratio of serum HBV DNA: (HBV DNA + HBV RNA) to assess the reverse transcriptional efficiency of pgRNA (f). Abbreviations: IT: immune-tolerant phase; IC: immune-clearance phases; LR: low-replicated phase; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBcrAg: hepatitis B core-related antigen; cccDNA: covalently closed circular DNA; n: number of cases; *** P < 0.0001; ** P < 0.001; * P < 0.01; ** P < 0.05; ns, P > 0.05.
without liver inflammation [4.24 (3.71, 4.41) vs. 3.65 (2.93, 3.99) log_{10} IU/mL, \( P < 0.01 \)] (Figure 4). However, such difference disappeared between the \( \geq G2 \) and the \( \leq G1 \) groups \([4.06 (3.27, 4.58) \) log_{10} IU/mL in \( \geq G2 \) group vs. \([3.89 (3.39, 4.25) \) log_{10} IU/mL in \( \leq G1 \) group, \( P = 0.627 \)] in the HBeAg-negative patients (Figure 4). Four patients in IT phase had undetectable anti-HBc levels and their liver inflammatory scores were all \( \leq G1 \). The clinical information of these four patients is shown in Supplementary Table 1 and their HBsAg and HBcrAg immunohistochemistry is shown in Figure 5.

Lastly, receiver-operating characteristic curve (ROC) assessment of the potential use of serum anti-HBc to distinguish patients with and without liver inflammation (\( \leq G1 \) or \( \geq G2 \)). As shown in Figure 4, the area under the ROC curve (AUC) \([95\% \) CI] was 0.76 \((0.67, 0.83)\), and the sensitivity and specificity were 75.00% and 71.43%, when taken a 4.00 log_{10} IU/mL serum anti-HBc cutoff according to the Youden index. The AUC increased to 0.79 \((0.67, 0.88)\) in HBeAg-positive patients, with sensitivity as 72.22% and specificity as 78.85%; the AUC decreased to 0.72 \((0.56, 0.85)\) in HBeAg-negative patients (sensitivity: 75.00%, specificity: 62.16%). At the cutoff value of 40 IU/L, the AUC (95\% CI) of ALT was as high as 0.87 \((0.76, 0.89)\) in all patients (sensitivity: 85.00%, specificity: 57.14%). The combined AUC (95\% CI) for ALT plus anti-HBc levels was 0.88 \((0.80, 0.93)\), with same sensitivity (85.00\%) but improved specificity (73.63\%), as compared to that of ALT alone (Figure 4).

### 4. Discussion

In this cross-sectional study, the dynamic changes of serum anti-HBc, HBV RNA, and HBcrAg levels, the classic markers HBsAg, HBV DNA, and ALT levels, and intrahepatic cccDNA levels across the distinct disease phases were characterized in treatment-naive chronic HBV-infected patients. To our knowledge, few studies have comprehensively investigated all these serum and intrahepatic HBV markers, mainly restricted by obtaining biopsies from patients across distinct phases.

Consistent with the previous report [13], our results here in this study also showed that serum HBV RNA and HBcrAg levels were significantly higher in the IT- and IC-phase patients than in the LR- and reactivation-phase patients. Perhaps due to the reduced amount of cccDNA and suppressed transcriptional activity in HBeAg-negative patients [24, 25], the detection rate of serum HBV RNA and HBcrAg in HBeAg-negative patients were 26.83% (11 patients) and 33.66% (22 patients), respectively. Therefore, considering the low detection rates and levels of HBV RNA and HBcrAg, HBV DNA should be compared to monitor HBeAg-negative CHB in clinical practice. Consistent with the previous report [26], a good correlation between serum HBcrAg level and levels of HBV DNA and HBV RNA was observed in our analysis, higher than their correlation with other serum and intrahepatic HBV markers involved in the analysis.

We further verified that serum HBV RNA and HBcrAg levels could reflect intrahepatic cccDNA levels in patients at both HBeAg-positive and HBeAg-negative phases. In a total of 111 patients, the Spearman correlation coefficients \((r)\) between intrahepatic cccDNA and serum HBV RNA, HBcrAg, and classical serum HBV DNA and HBsAg were 0.79, 0.78, 0.81, and 0.61, respectively. Comparatively, the correlation between HBsAg and other HBV markers involved in the analysis was relatively weak \((r \leq 0.70)\), especially for LR- and reactivation-phase patients. A potential explanation could be that serum HBV RNA and HBcrAg were only derived from cccDNA; in contrast, HBsAg could be derived from either cccDNA or integrated HBV DNA fragments [27]. Therefore, serum HBV RNA and HBcrAg levels may more accurately indicate intrahepatic cccDNA levels, and this makes them more potential to serve as...
HBeAg (+) (n = 70)

HBeAg (–) (n = 41)

- G0-1
- G2-3

Figure 4: Continued.
surrogate markers for intrahepatic cccDNA. However, the correlation coefficients between various serum markers and cccDNA from strong to weak was HBV DNA > HBV RNA = HBcAg > HBeAg > HBsAg. Thus, unlike in antiviral-treated patients, serum HBV RNA and HBcAg levels seem not superior to serum HBV DNA levels in reflecting cccDNA level in treatment-naïve patients.

In addition, the study here also found that HBeAg-positive patients (IT and IC) showed a higher transcriptional efficiency of cccDNA than HBeAg-negative patients (LR and Reactivation). The same was true if the numerator of this ratio is not serum HBV RNA but serum HBV DNA and HBcAg. HBeAg seroconversion may reduce cccDNA transcription efficiency by epigenetic silence and cccDNA’s mutation accumulation. However, HBeAg-positive patients showed a lower ratio of serum HBsAg to intrahepatic cccDNA than that in HBeAg-negative patients. Integrated HBV DNA may contribute to infection persistence by maintaining the liver expression of HBsAg, without generation of HBV RNA, HBcAg, and HBV DNA from cccDNA [28]. Furthermore, the data here demonstrated that unlike the inferior reverse transcription efficiency in HBeAg-positive patients, HBeAg-negative patients could maintain a more efficient reverse transcription to turn pgRNA into rcDNA, providing evidence that HBV DNA is more easily detected than HBV RNA in LR- and reactivation-phase patients.

As an indicator of host immune response to HBV infection, the pattern of serum anti-HBc level was quite different...
from those of serum HBV DNA, HBV RNA, and HBcrAg levels across distinct phases. The results of the study showed that the serum anti-HBc level of the IT-phase patients was lower than that of the other three phase patients, and only IT-phase patient's serum anti-HBc levels and cccDNA levels had a negative correlation. These results implicated presence of active anti-HBV-specific immune response even in patients in the IT phase, and support that serum anti-HBc levels are closely associated with both HBV replication and host immune response [29]. Another supporting evidence is that four IT-phase patients were found with undetectable anti-HBc and had a high viral replication but with non to mild histological liver inflammation. It is speculated that a high viral load concomitant with a large number of naked capsid particles may exhaust the low levels of anti-HBc produced in patients in the IT phase [30].

Serum HBV RNA level has been previously reported to reflect liver histological changes in NAs-treated CHB patients [8]. In this study, serum anti-HBc was found to be the only marker associated with liver inflammation by univariate and multivariate analyses. In the HBeAg-positive patients, patients with moderate/severe liver histological changes had significantly higher serum anti-HBc levels than those with no/mild liver histological changes. In all patients, although the AUC to indicate liver inflammation by serum anti-HBc level was lower than that by ALT level (0.76 vs. 0.87), the combination of the two greatly improved the specificity (57.14% vs. 73.63%). Notably, serum anti-HBc levels with a cutoff value of 4.00 log10 IU/mL to indicate liver inflammation had a higher specificity in HBeAg-positive patients (78.85%) than in HBeAg-negative patients (62.16%), suggesting that serum anti-HBc level can better mirror hepatic inflammation in HBeAg-positive patients than in HBeAg-negative patients. Therefore, serum anti-HBc level can compensate for the weak specificity of ALT in distinguishing HBV-related liver inflammation.

The study has limitations. The sample size, especially for the reactivation-phase group, was relatively small (12 patients). In addition, limited liver biopsies from HBeAg-negative patients with moderate/severe liver inflammation were obtained. All of these result in reduced statistical power.

In summary, we provided a comprehensive picture of all these serological markers in untreated patients across the distinct phases of chronic HBV infection (Figure 6). Serum HBV RNA and HBcrAg levels could mirror intrahepatic cccDNA levels across the distinct phases in treatment-naive CHB patients, but the two serum markers seemed not superior to serum HBV DNA. Other major findings were that serum anti-HBc level was negatively linked with cccDNA level in IT phase rather than the other three phases; and serum anti-HBc level could better mirror liver inflammation in HBeAg-positive patients than in HBeAg-negative patients. These findings further our understanding of the clinical values of the novel serum HBV markers that may help the management of CHB.

**Figure 6:** Schematic diagram of HBV serum markers and intrahepatic cccDNA levels across the distinct phases of chronic HBV infection. Abbreviations: cccDNA: covalently closed circular DNA; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBcrAg: hepatitis B core-related antigen; anti-HBc: hepatitis B core antibody; tDNA: total DNA.
Data Availability

The authors confirm that the data supporting the findings of this study are available on the request from the corresponding author.

Ethical Approval

The study protocol was approved by the Ethics Committee of the Fifth Medical Center of PLA General Hospital.

Conflicts of Interest

The authors Hao Liao, Le Li, Wei V. Zheng, Jun Zou, Guangxin Yu, Lanlan Si, Feilin Ge, Tao Zhou, Dong Ji, Xiangmei Chen, Guanxun Cheng, Dongping Xu, Yan Liu, and Junhui Chen declare that they have no conflict of interest.

Authors’ Contributions

Hao Liao and Yan Liu contributed to the study concept and design. Yan Liu, Guanxun Cheng, and Junhui Chen contributed to supervising the experiments. Hao Liao, Le Li, and Wei V. Zheng were responsible for patient selection/inclusion. Le Li, Jun Zou, Guangxin Yu, and Tao Zhou acquired experiment and detection data. Hao Liao, Lanlan Si, Feilin Ge, and Dong Ji contributed to analysis and interpretation of data. Hao Liao, Guanxun Cheng, Dongping Xu, Yan Liu, and Junhui Chen drafted the manuscript. Dongping Xu was responsible for revising the manuscript. Dongping Xu, Yan Liu, and Hao Liao contributed to funding acquisition. All authors contributed to critical revisions and approval of the final manuscript.

Acknowledgments

We would like to thank all donors for donating research blood samples and liver biopsies. We are grateful to Zengtao Yao and Jiuzeng Dai for their professional technical support. This study was supported by China Postdoctoral Science Foundation (2019TQ0206), National 13th Five-Year Special Grand Project for Infectious Disease (2017ZX10302201-001), Guangdong Basic and Applied Basic Research Foundation (2019A1515110615), National Natural Science Foundation of China (81721002), Shenzhen Key Medical Discipline Construction Fund (SZXK078), Ministry of Science and Technology of China (YCYZYP[2020]09), and Sanming Project of Medicine in Shenzhen (SZSM201612071).

Supplementary Materials

Supplementary Table 1. Clinical and virological details of the four anti-HBc-negative individuals. (Supplementary Materials)

References

[1] J. Liu, W. Liang, W. Jing, and M. Liu, "Countdown to 2030: eliminating hepatitis B disease, China," Bulletin of the World Health Organization, vol. 97, no. 3, pp. 230–238, 2019.
[2] European Association for the Study of the Liver, “EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection,” Journal of Hepatology, vol. 67, no. 2, pp. 370–398, 2017.
[3] N. A. Terrault, N. H. Bzowej, K. M. Chang et al., “AASLD guidelines for treatment of chronic hepatitis B,” Hepatology, vol. 63, no. 1, pp. 261–283, 2016.
[4] M. Nassal, "HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B," Gut, vol. 64, no. 12, pp. 1972–1984, 2015.
[5] J. Petersen, A. J. Thompson, and M. Leverro, "Aiming for cure in HBV and HDV infection," Journal of Hepatology, vol. 65, no. 4, pp. 835–848, 2016.
[6] C. H. Z. Siederdissen, B. Maasoumy, and M. Cornberg, "What is new on HBsAg and other diagnostic markers in HBV infection?", Best Practice & Research. Clinical Gastroenterology, vol. 31, no. 3, pp. 281–289, 2017.
[7] J. Wang, T. Shen, X. Huang et al., "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound," Journal of Hepatology, vol. 65, no. 4, pp. 700–710, 2016.
[8] J. Wang, Y. Yu, G. Li et al., "Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients," Journal of Hepatology, vol. 50168-8278, no. 17, pp. 32261–32264, 2017.
[9] K. Giersch, L. Allweiss, T. Volz, M. Dandri, and M. Lütgehetmann, "Serum HBV pgRNA as a clinical marker for cccDNA activity," Journal of Hepatology, vol. 66, no. 2, pp. 460–462, 2017.
[10] F. Van Bommel, A. Bartens, A. Mysickova et al., "Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors," Hepatology, vol. 61, no. 1, pp. 66–76, 2015.
[11] M. S. Farag, M. J. H. Van Campenhout, M. Pfefferkorn et al., "Hepatitis B virus RNA as early predictor for response to PEGylated interferon Alpha in HBeAg-Negative chronic hepatitis B," Clinical Infectious Diseases, vol. 72, no. 2, pp. 202–211, 2021.
[12] J. Wang, X. Chen, Y. Wu et al., "Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion," Hepatology Communications, vol. 2, no. 10, pp. 1168–1171, 2018.
[13] B. Testoni, F. Lebosse, C. Scholtes et al., "Serum hepatitis B core-related antigen (HBcAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients," Journal of Hepatology, vol. 70, no. 4, pp. 615–625, 2019.
[14] M. R. Brunetto, I. Carey, B. Maasoumy et al., "Incremental value of HBcAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis," Alimentary Pharmacology and Therapeutics, vol. 53, no. 6, pp. 733–744, 2021.
[15] H. Liao, Y. Liu, X. Li et al., "Monitoring of serum HBV RNA, HBcAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy," Antiviral Therapy, vol. 24, no. 2, pp. 105–115, 2019.
[16] R. Fan, J. Sun, Q. Yuan et al., "Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues," Gut, vol. 65, no. 2, pp. 313–320, 2016.
[17] F. Q. Hou, L. W. Song, Q. Yuan et al., “Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon,” Theranostics, vol. 5, no. 3, pp. 218–226, 2015.

[18] J. Zhou, L. Song, H. Zhao et al., “Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase,” Scientific Reports, vol. 7, no. 1, p. 2747, 2017.

[19] J. Li, T. Y. Zhang, L. W. Song et al., “Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels,” Hepatology Research, vol. 48, no. 3, pp. E133–E145, 2018.

[20] S. K. Sarin, M. Kumar, G. K. Lau et al., “Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update,” Hepatology International, vol. 10, no. 1, pp. 1–98, 2016.

[21] P. Bedossa and T. Poynard, “An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group,” Hepatology, vol. 24, no. 2, pp. 289–293, 1996.

[22] Y. Zhong, J. Han, Z. Zou et al., “Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR,” Clinica Chimica Acta, vol. 412, no. 21-22, pp. 1905–1911, 2011.

[23] H. Liao, Y. Liu, J. Wang et al., “Letter to the Editor: The differences between the reverse transcriptional efficiency of HBV pregenomic RNA and transcriptional efficiency of HBV covalently closed circular DNA,” Hepatology, vol. 74, no. 3, pp. 1720–1721, 2021.

[24] L. Y. Mak, G. Cloherty, D. K. Wong et al., “HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy,” Hepatology, vol. 73, no. 6, pp. 2167–2179, 2020.

[25] A. Suslov, M. A. Meier, S. Ketterer, X. Wang, S. Wieland, and M. H. Heim, “Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity,” Journal of Hepatology, vol. 74, no. 4, pp. 794–800, 2021.

[26] L. Wang, X. Cao, Z. Wang et al., “Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-Positive chronic hepatitis B patients,” Journal of Clinical Microbiology, vol. 57, no. 1, 2019.

[27] M. Lindh, G. E. Rydell, and S. B. Larsson, “Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies,” Current Opinion in Virology, vol. 30, pp. 24–31, 2018.

[28] T. Tu, M. A. Budzinska, N. A. Shackel, and S. Urban, “HBV DNA integration: molecular mechanisms and clinical implications,” Viruses, vol. 9, no. 4, p. 75, 2017.

[29] T. Vanwolleghem, Z. M. A. Groothuismink, K. Kreeft, M. Hung, N. Novikov, and A. Boonstra, “Hepatitis B corespecific memory B cell responses associate with clinical parameters in patients with chronic HBV,” Journal of Hepatology, vol. 73, no. 1, pp. 52–61, 2020.

[30] B. Jiang and E. Hildt, “Intracellular trafficking of HBV particles,” Cell, vol. 9, no. 9, p. 2023, 2020.